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Over the last few years, increasing evidence has become
available that some brominated flame retardants (BFRs) may
have endocrine-disrupting (ED) potencies. The goal of the current
study was to perform a systematic in vitro screening of the ED
potencies of BFRs (1) to elucidate possible modes of action of
BFRs in man and wildlife and (2) to classify BFRs with similar
profiles of ED potencies. A test set of 27 individual BFRs were
selected, consisting of 19 polybrominated diphenyl ether con-
geners, tetrabromobisphenol-A, hexabromocyclododecane, 2,4,6-
tribromophenol, ortho-hydroxylated brominated diphenyl ether
47, and tetrabromobisphenol-A–bis(2,3)dibromopropyl ether. All
BFRs were tested for their potency to interact with the arylhy-
drocarbon receptor, androgen receptor (AR), progesterone re-
ceptor (PR), and estrogen receptor. In addition, all BFRs were
tested for their potency to inhibit estradiol (sulfation by estradiol
sulfotransferase (E2SULT), to interfere with thyroid hormone
3,3#,5-triiodothyronine (T3)–mediated cell proliferation, and to
compete with T3-precursor thyroxine for binding to the plasma
transport protein transthyretin (TTR). The results of the in vitro
screening indicated that BFRs have ED potencies, some of which
had not or only marginally been described before (AR antagonism,
PR antagonism, E2SULT inhibition, and potentiation of T3-
mediated effects). For some BFRs, the potency to induce AR
antagonism, E2SULT inhibition, and TTR competition was higher
than for natural ligands or clinical drugs used as positive controls.
Based on their similarity in ED profiles, BFRs were classified into
five different clusters. These findings support further investigation
of the potential ED effects of these environmentally relevant
BFRs in man and wildlife.
Key Words: toxicity profiling; brominated flame retardants;
endocrine disruption; hierarchical cluster analysis; principal
component analysis.
Problem
Over the past 50 years, petroleum-based polymeric materials
have increasingly been used in construction materials, textiles,
and computer equipment. To meet fire safety regulations for
consumers of these products, flame retardants are incorporated
in these inflammable polymers to increase their fire resistance.
About 25% of the annual flame retardant production consists of
halogenated organics, of which brominated flame retardants
(BFRs) are the most important (Alaee et al., 2003). Although
BFRs are beneficial to mankind due to their flame-retarding
characteristics, some may also pose a health risk to man and the
environment, given their persistent, bioaccumulating, and
suspected endocrine-disrupting (ED) potencies.
Characteristics of BFRs
Of all BFRs, tetrabromobisphenol-A (TBBPA), polybromi-
nated diphenyl ethers (PBDEs), and hexabromocyclododecane
(HBCD) have the highest consumption figures in the world.
TBBPA is produced by bromination of bisphenol-A (Fig. 1).
With an estimated global consumption of 210,000 tons in 1999,
TBBPA is the most widely used BFR in the world (Alaee et al.,
2003). PBDEs are characterized by two brominated phenyl
rings, connected by an ether bridge (Fig. 1). As all 10 hydrogen
groups of diphenyl ether may be exchanged with bromine
during production, theoretically 209 different PBDE congeners
can be distinguished. Given the structural similarity between
PBDEs and polychlorinated biphenyls (PCBs), PBDEs follow
the PCB nomenclature proposed by Ballschmitter and Zell
(1980). PBDEs are typically produced in three different
commercial mixtures, each with its own average level of
bromination, i.e., penta-PBDE, octa-PBDE, and deca-PBDE
mixtures. The commercial penta-PBDE mixture Bromkal 70-
5DE consists of 80% of only three congeners, i.e., 35%
brominated diphenyl ether (BDE) 47, 38% BDE-99, and 7%
BDE-100 (Fig. 1) (Sjo¨din et al., 1998). Octa-PBDE products
from different suppliers have different PBDE composition, but
in general, hepta-brominated BDE-183 (Fig. 1) is the major
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congener (± 44%; Sjo¨din, 2000). The deca-PBDE mixture
contains > 97% BDE-209 (Fig. 1) (Marsh, 2003). In 1999,
global market demands of penta-, octa-, and deca-PBDE
mixtures were 8500, 3825, and 54,800 tons, respectively
(Alaee et al., 2003). HBCD is the third BFR in production
volume with an estimated European market volume of 8950
tons in 1999 (Danish EPA, 1999). HBCD (Fig. 1) is produced
by bromination of cyclododecatriene, resulting in three differ-
ent diastereoisomers (alpha, beta, and gamma). Commercial
technical HBCD mixtures typically contain 70–90% of the
gamma diastereoisomer (Zegers et al., 2005).
Exposure to BFRs
Several studies have demonstrated that man and wildlife are
exposed to BFRs due to their presence in the environment and
their bioaccumulating properties (see reviews by Darnerud
et al., 2001; Law et al., 2003; Sjo¨din et al., 2003; Vos et al.,
2003). In short, PBDEs, HBCD, and, to a lesser extent, TBBPA
are persistent BFRs with bioaccumulating potencies in the
aquatic food chain (e.g., Lindberg et al., 2004; Morris et al.,
2004; Zegers et al., 2005) and in man (Darnerud et al., 2001;
Weiss et al., 2004). In general, PBDEs and HBCD are
recognized as persistent organic pollutants in the abiotic
environment. HBCD and tetra- to hexa-brominated BDE-47,
BDE-99, BDE-100, BDE-153, and BDE-154 also dominate
BFR composition in biota (including man), but BDE-209 and
TBBPA are hardly found in biota, possibly due to low uptake
rate or rapid excretion after biotransformation (Boon et al.,
2002; Law et al., 2003).
ED Potency of BFRs
Over the last few years, increasing evidence has become
available that some BFRs may have ED potencies (Darnerud
et al., 2001; Legler and Brouwer, 2003; Vos et al., 2003). The
structural resemblance between TBBPA and PBDEs to thy-
roxine (T4), which is the precursor of the active thyroid
hormone 3,3#,5-triiodothyronine (T3), may explain the re-
ported interaction of these BFRs with the thyroid axis. In vitro
studies demonstrated the T3-like activity of TBBPA and
HBCD (Kitamura et al., 2002, 2005; Schriks et al., 2006;
Yamada-Okabe et al., 2005). For TBBPA and hydroxylated
PBDEs, Meerts et al. (2000) found in vitro competition with T4
for binding to human transthyretin (TTR), the T4-transporting
protein in plasma. Decreased plasma T4 levels found in rodents
exposed to PBDEs (Zhou et al., 2001, 2002) may be attributed
to reduced TTR-mediated transport. Alternative explanations
are an induced T4 turnover by induced levels of hepatic uridine
phosphoglucuronyl transferase, whereas effects on the thyroid
gland or thyroid-stimulating hormone levels are less likely
(Zhou et al., 2001, 2002). Plasma T4 decreases may be
involved in the developmental neurotoxic and behavioral
effects described for rodents exposed to BFRs (PBDEs and
HBCD) and other polyhalogenated aromatic hydrocarbons
(Branchi et al., 2003; Eriksson et al., 2002; Porterfield, 2000;
Viberg et al., 2003).
In addition, (anti-)estrogenic properties have been demon-
strated in vitro for BFRs. Meerts et al. (2001) found that the
estrogen receptor (ER) was activated by lower-brominated
PBDEs and inactivated by higher-brominated (hydroxylated)
PBDEs. Kester et al. (2002) proposed an alternative (non–ER-
regulated) estrogenic mechanism by the inhibition of estradiol
sulfotransferase enzymes, leading to a decreased sulfation of
estradiol (E2) and an associated increased bioavailability of
endogenous estrogens. Estrogenic effects of BFRs have hardly
been studied in vivo. For TBBPA, estrogenic effects were
observed in the mouse uterotropic assay (Kitamura et al.,
2005), whereas no effects were found on quail and chicken
embryo development (Berg et al., 2001).
Recently, Stoker et al. (2005) demonstrated in vivo antian-
drogenic properties of PBDEs. In a pubertal exposure study
with male Wistar rats exposed to the commercial penta-PBDE
mixture DE-71, the authors found delayed puberty and
a corresponding suppression of ventral prostate and seminal
vesicle growth. DE-71 was also found to be antiandrogenic in
an immature rat Hershberger assay. Additional in vitro studies
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FIG. 1. Molecular structures of BFRs selected for this study. For PBDEs
only a general structure and some environmentally relevant representatives are
shown.
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indicated that the DE-71 constituents BDE-47, BDE-99,
BDE-100, and BDE-154 inhibited binding of the synthetic
androgen R1881 to cytosolic androgen receptor (AR) from the
ventral prostate. For BDE-100, this inhibition was demonstrated
to be purely competitive. Of the four AR-binding PBDE con-
geners, BDE-47 and BDE-100 also inhibited dihydrotestosterone-
induced, human AR-regulated transcriptional activation in a
luciferase reporter gene assay (Stoker et al., 2005).
Finally, some PBDE congeners can activate or inactivate the
arylhydrocarbon receptor (AhR, or dioxin receptor [DR];
Behnisch et al., 2003; Meerts et al., 1998), which is directly
involved in the expression of cytochrome P450-1A. In vivo,
increased hepatic ethoxyresorufin O-deethylase (EROD) activ-
ity has been demonstrated in rats exposed to PBDEs (e.g., Zhou
et al., 2001, 2002). With respect to endocrine disruption, in-
duced or inhibited DR-regulated enzyme activities may directly
or indirectly affect critical pathways in vitamin A metabo-
lism (Zile, 1992) or steroidogenesis (Fukazawa et al., 2004).
Aim of This Study
Despite indications for bioaccumulating and the ED prop-
erties of BFRs, a human and ecological risk assessment for
these compounds has been hampered by the lack of a systematic
identification and toxicological characterization of the most
potent and environmentally relevant BFRs (Vos et al., 2003).
The goal of the current study was to perform a systematic
in vitro screening of the potential ED potencies of BFRs, as part
of a hazard identification approach within the EU-funded
research program FIRE (RIVM, 2003). For the in vitro
screening, a test set of 27 individual BFRs were selected,
consisting of TBBPA, 19 PBDEs, HBCD (technical mixture
[TM] and the alpha, beta, and gamma diastereoisomers), 2,4,6-
tribromophenol (246-TBP), and ortho-hydroxylated bromi-
nated diphenyl ether 47 (6OH-BDE-47). The test set further
included tetrabromobisphenol-A–bis(2,3)dibromopropyl ether
(TBBPA-DBPE), which is used as a flame-retarding additive
for plastics. The subset of PBDEs contained environmentally
relevant and also less environmentally relevant congeners. The
latter were selected to cover a broad variation in chemical
characteristics in the test set, to allow the establishment of
quantitative structure-activity relationships (QSARs) that will
be described elsewhere (Harju et al., in press). The test set was
completed by commercial penta- and octa-PBDE mixtures. All
compounds were tested for their potency to interfere via
thyroidal, estrogenic, and AhR-mediated pathways. In addi-
tion, the potency to interfere with androgenic and progesta-
genic pathways was tested for the first time for BFRs.
Altogether, all compounds were tested in seven different bioas-
says for 12 endocrine-related modes of action (Table 1). Results
from the in vitro screening were used for (1) identification
of relevant endocrine-related modes of action that may be af-
fected by BFRs in man and wildlife and (2) classification of
BFRs with similar ED profiles.
MATERIALS AND METHODS
Brominated flame retardants. BDE-28 [bromine substitution pattern
2,4,4#], BDE-47 [2,2#,4,4#], BDE-49 [2,2#,4,5#], BDE-99 [2,2#,4,4#,5],
BDE-100 [2,2#,4,4#,6], BDE-153 [2,2#,4,4#,5,5#], BDE-155 [2,2#,4,4#,6,6#],
BDE-169 [3,3#,4,4#,5,5#], BDE-181 [2,2#,3,4,4#,5,6], BDE-183 [2,2#,3,4,4#,5#,6],
BDE-190 [2,3,3#,4,4#,5,6], BDE-206 [2,2#3,3#,4,4#,5,5#,6], and BDE-209
[2,2#3,3#,4,4#,5,5#,6,6#] and 6OH-BDE-47 (> 99%; cleaned up on charcoal
column to remove possible impurities of brominated dibenzofurans and
dioxins) were obtained from Stockholm University through Dr Go¨ran Marsh
and Dr A˚ke Bergman. BDE-19 [2,2#,6], BDE-38 [3,4,5], BDE-39 [3,4#,5],
BDE-79 [3,3#,4,5#], BDE-127 [3.3#4,5,5#], and BDE-185 [2,2#,3,4,5,5#,6] (>
98%) were bought from AccuStandard (New Haven CT). Penta-PBDE mixture
DE-71 and octa-PBDE mixture Octa LM were obtained from Great Lakes
TABLE 1
Overview of the Seven In Vitro Bioassays Used to Determine the Possible ED Potency of BFRs on 12 Different Endpoints
Ordered per Endocrine Pathway
Endocrine pathway Bioassay Reference material Endpoint
AhR mediated DR-CALUX TCDD Dioxin-like activity through DR
2,2#3,3#,4,4#-Hexachlorobiphenyl
(PCB-128)
Anti–dioxin-like activity through DR in the presence of TCDD
Androgenic AR-CALUX DHT Androgenic activity through AR
Flutamide Antiandrogenic activity through AR in the presence of DHT
Progestagenic PR-CALUX MPA Progestagenic activity through PR
RU-486 Antiprogestagenic activity through PR in the presence of MPA
Estrogenic ER-CALUX 17b-E2 Estrogenic activity through ER
ICI 182,780 Antiestrogenic activity through ER in the presence of E2
E2SULT PCP Inhibited sulfation of E2
Thyroidal TTR binding T4 Displacement of thyroid hormone precursor (T4) from its
plasma transport protein TTR
T-Screen T3 Thyroid hormone–mimicking (T3 like) activity
Amiodarone Anti–T3-like activity in the presence of T3
Note. DHT: Dihydrotestosterone; MPA: medroxyprogesterone acetate.
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Chemical Corporation (West-Lafayette IL) and Dead Sea Bromine Group
(Beer-Sheva, Israel), respectively, and were cleaned up on charcoal column
before testing. Based on the PBDE composition of the mixtures (Sjo¨din, 2000),
average molecular weights of 471.9 and 758.1 were estimated for penta- and
octa-PBDE mixtures, respectively. TBBPA (> 97%) and 246-TBP (> 98%)
were obtained from Aldrich (Milwaukee WI), HBCD (TM containing about
90% gamma diastereoisomer) from Dead Sea Bromine Group, HBCD
diastereoisomers (> 97%) from Cambridge Isotope Laboratories (Andover
MA), and TBBPA-DBPE (TM) from Broomchemie BV (Terneuzen, Nether-
lands).
For all compounds, stock solutions were prepared in dimethylsulfoxide
(DMSO) by (1) dissolving the compounds in tetrahydrofurane (THF; Sigma-
Aldrich [St. Louis MO]; 99.5%), (2) transferring the solutions to DMSO (Acros
[Geel, Belgium]; 99.9%), and (3) evaporating the THF under a gentle stream of
nitrogen. Final BFR concentrations in the DMSO stocks were 2.5mM, except
for BDE-209 for which a stock solution of 1.5mM was prepared due to
solubility problems at higher concentrations.
CALUX bioassays. For all test compounds, the potency to interact as an
agonist or antagonist with the AhR, the ER, the AR, and the progesterone
receptor (PR) was determined in the DR-, ER-, AR-, and PR-CALUX
bioassays, respectively (Legler et al., 1999; Murk et al., 1996; Schreurs
et al., 2005). All four CALUX bioassays (chemically activated luciferase gene
expression; BioDetection Systems BV [BDS], Amsterdam, The Netherlands)
make use of reporter cell lines carrying a luciferase gene under the
transcriptional control of response elements for activated receptors. The four
CALUX bioassays were performed according to protocols from BDS.
Methodological differences among the four CALUX bioassays are indicated
in Table 2. In short, cells were plated in 96-well plates with the medium
supplemented with fetal calf serum (FCS; Table 2). After a given period of time
(see Table 2), the medium was refreshed with exposure medium containing the
BFR to be tested (maximum concentration 10 or 12.5lM), in the absence or in
the presence of a reference agonist. After 24 h of incubation, the medium was
removed; cells were lysed in 30 ll of Triton-lysis buffer and measured for
luciferase activity using a luminometer.
Estradiol sulfotransferase assay. The estradiol sulfotransferase
(E2SULT)–inhibiting potency of BFRs was determined according to Kester
et al. (2000) with minor modifications. In short, the effect of BFRs on the
formation of E2 sulfate was determined after incubation of tritium-labeled
estradiol (3H-E2), sulfotransferase, and the cofactor 3#-phosphoadenosine-5#-
phosphosulfate (PAPS). Recombinant human sulfotransferase 1E1 (SULT1E1)
expressed in a V79-1E1 Chinese hamster cell line (Czich et al., 1994) was
kindly provided by Prof. Dr H. Glatt (German Institute of Human Nutrition).
SULT1E1 was incubated (37C; 30 min; 2 lg cytosolic protein/ ml) with 1nM
3H-E2 (2,4,6,7,16,17-3H-estradiol; Amersham Biosciences [Buckinghamshire,
UK]) and 50lM PAPS (Sigma-Aldrich) in 0.2 ml of 0.1M sodium phosphate
(pH 7.2), 2mM EDTA, and 1mM dithiothreitol in the presence or absence
(control) of the test compound (maximum concentration 10lM) or pentachlo-
rophenol (PCP), used as a reference material (Kester et al., 2000). Maximum
concentration of the test compounds during incubation was 10lM, and all
incubations contained 1% DMSO. Blank incubations received no PAPS. The
reaction was stopped by adding 800 ll of ice-cold water. Unreacted 3H-E2 was
removed by extraction of the incubation mixture with 2 ml of dichloromethane.
The amount of water-soluble 3H-E2 sulfate was quantified by counting 0.5 ml
of the water phase in a beta counter (LKB Wallack 1219 Rackbeta).
TTR-binding assay. The capacity of BFRs to compete with T4 for binding
to TTR was investigated according to Lans et al. (1993) with modifications.
Human TTR (prealbumin from human plasma, Sigma-Aldrich; 30nM) was
incubated overnight at 4C in a final volume of 200 ll 0.1M Tris-HCl buffer
(pH 8.0; 0.1M NaCl, 0.1mM EDTA) with a mixture of 125I-labeled (L-3#-
5#-125I-thyroxine, Amersham Biosciences) and -unlabeled (Sigma-Aldrich) T4
(55nM; 100,000 cpm) and test compounds (maximum concentration 62.5lM)
or cold T4 (reference material) as competitors. All treatments and carrier
controls contained 2.5% DMSO. When binding equilibrium was reached, TTR-
bound and free 125I-T4 were separated on 1-ml Biogel P-6PG columns and
spin-force eluted with 200 ll Tris-HCl buffer (1 min, 100g, 4C). The TTR-
bound 125I-T4–containing eluate was counted for radioactivity on a gamma
counter (LKB Wallack 1282 Compu-gamma CS) and corrected for the initial
amount of 125I-T4 added to the incubation mixture that had been counted before
incubation started.
T-Screen. BFR potency to act as a thyroid hormone receptor (TR) agonist
or antagonist was tested in the T-Screen (Gutleb et al., 2005), a functional assay
TABLE 2
Differences in Experimental Characteristics of the CALUX Assays
Experimental characteristic DR-CALUX AR-CALUX PR-CALUX ER-CALUX
Cell type H4IIE (rat hepatoma) U-2 OS (human osteoblast) U-2 OS (human osteoblast) T47D (human breast cancer)
Initial cell density (cells per well) Not determineda 6000 4000 7500
Medium (GIBCO) a-MEMb with phenol red Phenol red–free DF medium Phenol red–free DF medium Phenol red–free DF medium
1.26 g/l NaHCO3 13
nonessential amino acids
FCS (GIBCO) (% in medium) 10% 5% DCCb 5% DCCb 5% DCCb
Time between plating and
exposing of the cells (h)
24 48 48 48
Final concentration (pM) of
reference agonist added
(1–2 3 EC50) to determine
antagonistic potencyc
15 164 98 6
Final DMSO concentration
(% vol/vol)
0.4 0.2 0.2 0.5
Maximum BFR concentration
(lM)
10 10 10 12.5
Final test volume (ll) 200 200 200 100
aTwenty-four hours after plating, the cells were confluent at the start of the exposure period.
bMEM: minimum essential medium; DCC: dextran-coated charcoal stripped.
cSee Table 3.
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based on the T3-dependent cell proliferation of a rat pituitary tumor cell line
(GH3) when plated at low density in serum-free medium. GH3 cells were
cultured (humid atmosphere, 37C, 5% CO2) in Dulbecco’s modified Eagle’s
medium/Ham’s F12 (DF medium; GIBCO [Breda, Netherlands]) supplemented
with 10% FCS (GIBCO) and 15mM HEPES (4-[2-hydroxyethyl]-1-piperazi-
neethanesulfonic acid). Prior to BFR exposure, cells were incubated for 48 h
in serum-free DF medium to deplete cells of thyroid hormones. On the day of
exposure, cells were plated on a transparent 96-microtiter plate (Greiner [Alphen
aan de Rijn, Netherlands]; 2500 cells per well). GH3 cells were exposed in
triplicate to a full dose-response range (0.001–1000nM) of reference material T3
or test chemicals (in the absence or presence of 0.25nM T3 [EC50]) in fresh DF
medium. All treatments and carrier controls contained 0.5% DMSO. After 96 h
of exposure, cell proliferation was determined by measuring the total metabolic
activity of the cells by adding 8 ll of resazurin (400lM in PBS; Sigma-Aldrich)
to each well. After 4 h of incubation (37C; 5% CO2), formation of the
fluorescent metabolite resorufin was determined in a fluorometer (Milli-pore
Cytofluor 2350; kex ¼ 530 nm; kem ¼ 590 nm) (O’Brien et al., 2000).
Cytotoxicity. To ensure that reduced activities in the various bioassays
were caused by true antagonistic responses and not by cytotoxicity, viability
was measured in DR-CALUX and ER-CALUX cells exposed to 10 or 12.5lM
BFR, which was the maximum concentration tested in the CALUX assays
(Table 2). As in the T-Screen, cell viability was measured as the metabolic
capacity to reduce blue resazurin into pink resorufin (O’Brien et al., 2000).
CALUX cells were plated as in the original CALUX assay. CALUX cells were
exposed for 24 h to exposure medium (cell-specific medium containing BFR
and 40lM resazurin), and metabolic capacity was determined spectrophoto-
metrically (SpectraMAX 340 PC) as a decrease of the blue-colored resazurin
(k ¼ 600 nm) in the assay medium.
Data analysis. For all bioassays, dose-response curves were determined
for those compounds showing effects > 20% of control level in earlier range-
finding experiments. EC50 or IC50 values were calculated for those compounds
for which a full dose-response curve could be constructed. For compounds
yielding responses between 10 and 50% of control level within the range of test
concentrations, EC50 or IC50 values were either extrapolated from the dose-
response curve (in case the extrapolated value was reasonably close to the
highest test concentration) or set at a minimum value (see Tables 4–8). In most
bioassays, dose-response curves reached maximum responses (sometimes after
extrapolation) comparable to the reference compound. For only a few DR-
agonistic and E2SULT-inhibiting BFRs, maximum responses were lower than
for reference compounds. In these cases (indicated by footnotes in Tables 4 and
7, respectively), EC50 or IC50 values were calculated as the concentration at the
point of inflection in the compound-specific dose-response curve and not as the
concentration corresponding with 50% of the maximum response induced by
the reference material. In vitro, ED potencies of all BFRs were classified
according to the criteria listed in Table 3. Classification was based on EC50 or
IC50 values, except for T-Screen results, which did not allow EC50 estimation
due to cytotoxicity. For each BFR, a compound-specific toxicity profile was
constructed including a set of 12 classified ED activities determined in vitro.
Toxicity profiles of all 27 BFRs were analyzed for common features using
two different pattern recognition methods: hierarchical cluster analysis and
principal component analysis (PCA). In both methods, the BFR-specific
toxicity profile is considered as a set of coordinates that define the position
of the BFR in a 12-dimensional space. Two different pattern recognition
methods were chosen to improve interpretation and to verify results from one
method with those from the other method.
Hierarchical cluster analysis (e.g., Aldender and Blashfield, 1984) is
a pattern recognition method that is solely based on the calculated distances
between the 27 BFRs within this 12-dimensional space. In the first stage, the
two BFRs with lowest distance are grouped together into a cluster. Next, an
average location for this cluster is calculated in the 12-dimensional space. In the
second stage, distances between the remaining 25 BFRs and the new cluster are
calculated and cases with lowest distance merged again. This can be a third and
a fourth BFR that merge into a second cluster, but also a third BFR that is added
to the first cluster. This procedure is repeated, adding BFRs to existing clusters,
creating new clusters, or combining clusters until only one cluster is left.
Results from a hierarchical cluster analysis may be presented in a so-called
dendrogram (see Fig. 3), a diagram that illustrates the fusions made at
successive stages of analysis and indicates the relative distance between the
different BFRs and clusters in the 12-dimensional space. Hierarchical cluster
analysis was performed in SPSS (version 10.0 for Windows) based on squared
Euclidean distances between class values using the between-group linkage
method.
In PCA (e.g., Jackson, 1991), the 27 BFRs located in the 12-dimensional
space are projected down to a lower-dimensional hyperspace. In Figure 4,
a score plot is shown where two latent explanatory variables (principal
components or PCs) are used as x-axis and y-axis. These two orthogonal
vectors are calculated in such a way that PC1 explains the largest part of the
total variance, PC2 the largest part of the remaining variance, etc. The score
plot yields an overview of the major patterns in the data set, and BFRs found
closely together have a similar toxicity profile. The distance of a particular BFR
to the origin indicates its deviation from the toxicity profile of the ‘‘average
BFR.’’ Similarly, the significance of the original 12 bioassay responses can be
illustrated in a so-called loading plot, where highly significant ED potencies
have a larger distance to the origin than less-significant potencies. By
superimposing the loading plot on the score plot (as done in Fig. 4), correlations
between BFRs and bioassay responses can be visualized: BFRs and bioassay
responses located closely together are positively correlated, whereas BFRs
and bioassay responses with opposite positions are negatively correlated. The
PCA calculations were performed in Simca-Pþ 10.0 (Umetrics Inc, Umea˚,
Sweden), using a cutoff in eigenvalue of 2 to define the number of significant
components.
RESULTS
CALUX Bioassays
Of the nine DR-agonistic PBDEs, only four (BDE-38, BDE-
153, BDE-190 and 6OH-BDE-47) were able to induce a full
TABLE 3
Criteria for Classification of BFRs Based on In Vitro Toxicity Results
Class Potency Criteria (all bioassays except T-Screen potentiation) Criteria T-Screen potentiationa
1 No potency Response < 20% of control at 10lM Additional response < 10%
2 Low potency (EC50 or IC50) > 10lM and response > 20% of control at 10lM 10% < additional response < 20%
3 Moderate potency 1lM < (EC50 or IC50) < 10lM 20% < additional response < 30%
4 High potency 0.1lM < (EC50 or IC50) < 1.0lM 30% < addition response < 40%
5 Very high potency 0.01lM < (EC50 or IC50) < 0.1lM 40% < additional response
aAdditional response as the percentage of maximum T3 response at the highest noncytotoxic concentration tested (0.5 or 1lM).
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dose-response curve up to the maximum induction found for
the most potent DR ligand 2,3,7,8-tetrachlorodibenzo-p-dioxin
(TCDD) (Table 4). The remaining five DR-agonistic PBDEs
(BDE-49, BDE-79, BDE-99, BDE-181, and BDE-183) reached
maximum induction levels between 52 and 63% of the TCDD
induction maximum and were therefore considered as partial
agonists (Fig. 2). Based on EC50 values, BDE-38 was the most
potent compound, with a DR-agonistic potency of about 56,000
times less than that of TCDD (Table 4). DR-antagonistic
activity was found for lower-brominated PBDEs (up to hexa-
brominated BDE-169) and to some extent for HBCD (Table 4).
BDE-47 was the most potent DR antagonist tested (IC50 ¼
2.7lM), with activities similar to the reference antagonist
PCB-128 (Fig. 2; Table 4).
No agonistic AR and PR activity could be demonstrated for
any of the BFRs tested. However, for 22 out of the 27 BFRs,
antiandrogenic and—to a lesser extent—antiprogestagenic
activities were found (Table 5). Only BDE-169, BDE-206,
BDE-209, TBBPA, and TBBPA-DBPE did not show any AR-
and PR-antagonistic activity. Highest AR antagonism was
found for BDE-19 and BDE-100 with IC50 values of 0.060
and 0.097lM, respectively (Table 5; Fig. 2). Together with
BDE-47 and BDE-49, these BFRs were more potent than the
antiandrogenic drug flutamide (IC50¼ 1.3lM) that was used as
a reference AR-antagonistic compound (Sonneveld et al.,
2005). PR-antagonistic activity was also highest for BDE-19
(IC50 ¼ 0.8lM). In addition, IC50 values of  5lM were found
for HBCD (TM and gamma diastereoisomer), BDE-100, BDE-
155, BDE-181, BDE-183, BDE-185, BDE-190, and 6OH-
BDE-47 (Table 5). All PR-antagonistic BFRs were more than
three orders of magnitude less potent than the pregnancy-
terminating and breast cancer drug RU-486 that was used as an
TABLE 4
AhR (DR)-Agonistic and -Antagonistic Responses of the 27 BFRs and Positive Controls TCDD and PCB-128 in
the DR-CALUX Assaya
DR agonistic DR antagonistic
Compound EC50 (lM) ± SD TCDD EF ± SD IC50 (lM) ± SD PCB-128 EF SD
BDE-19 — — — —
BDE-28 — — 4.5 ± 0.4 0.66 ± 0.05
BDE-38 0.5 ± 0.0 18 ± 3 3 106 — —
BDE-39 — — 13 ± 1 0.22 ± 0.02
BDE-47 — — 2.7 ± 0.7 1.1 ± 0.3
BDE-49 > 15b < 0.6 3 106 > 15 < 0.20
BDE-79 1.4 ± 0.3b 5.8 ± 0.2 3 106 — —
BDE-99 > 15b < 0.6 3 106 13 ± 0 0.22 ± 0.01
BDE-100 — > 15 < 0.20
BDE-127 — — 9.7 ± 0.9 0.31 ± 0.03
BDE-153 0.6 ± 0.2 15 ± 2 3 106 — —
BDE-155 — — — —
BDE-169 — — 6.2 ± 4.4 0.64 ± 0.46
BDE-181 4.5b ± 2.7 2.4 ± 1.9 3 106 — —
BDE-183 2.0b ± 0.1 4.4 ± 1.2 3 106 — —
BDE-185 — — — —
BDE-190 1.2 ± 0.3 7.1 ± 0.1 3 106 — —
BDE-206 — — — —
BDE-209 — — — —
TBBPA — — — —
246-TBP — — — —
6OH-BDE-47 1.3 ± 0.4 6.9 ± 0.8 3 106 — —
HBCD TM — — > 15 < 0.20
HBCD alpha — — 7.4 ± 1.8 0.42 ± 0.10
HBCD beta — — > 15 < 0.20
HBCD gamma — — 11 ± 2 0.29 ± 0.04
TBBPA-DBPE — — — —
Penta-mix — — 4.5 ± 1.2 0.68 ± 0.17
Octa-mix — — 2.8 ± 0.1 1.1 ± 0.0
TCDD 8.3 ± 1.5 3 106 1.0 ± 0.2 ND ND
PCB-128 ND ND 3.0 1
an  2; —: no response; ND: not determined.
bPartial agonists reaching maximum induction levels 52–63% of the maximum TCDD induction.
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FIG. 2. Typical examples of dose-response relationships determined for BFRs in the in vitro bioassays: agonistic and antagonistic responses towards the DR,
AR, PR, and ER; inhibition of E2SULT; competition with T4 for TTR binding; potentiation and antagonism of T3-mediated effects. For each mode of action,
results are presented for a reference compound (d) and one or more exemplary BFRs (n,:, ¤).
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antiprogestagenic reference compound (Mahajan and London,
1997).
ER-agonistic (i.e., estrogenic) responses were only found for
low-brominated diphenyl ethers (up to hexa-brominated BDE-
155), with EC50 values > 2lM (Table 6). Estrogenic potency of
BFRs was six orders of magnitude lower than for the natural
ligand E2, with highest potency for BDE-19 (EC50 ¼ 2.4lM;
Fig. 2) for which a molar E2 equivalency factor (E2 EF) of
1.26 3 10-6 was found (Table 6). ER-antagonistic (i.e., anti-
estrogenic) responses were found for tetra-brominated BDE-
79, all hepta-brominated PBDEs in the test set (i.e., BDE-181,
BDE-183, BDE-185, and BDE-190), HBCD, and the phenolic
compounds 6OH-BDE-47 and 246-TBP (but not TBBPA).
The most potent test compound was 6OH-BDE-47 (IC50 ¼
0.5lM; Fig. 2), which was 3000 times less potent than the
antiestrogenic drug ICI 182.780 (Table 6) that was used
a reference compound (Legler et al., 1999).
E2SULT Assay
TBBPAwas the most potent inhibitor of E2 sulfation (IC50¼
0.016lM), being almost 13 times more potent than the well-
known inhibitor PCP (Table 7; Fig. 2). 246-TBP and to a lesser
extent 6OH-BDE-47 were also potent E2SULT inhibitors,
indicating that the E2SULT-inhibiting potency is supported
by the presence of a hydroxylated aromatic group. Although
full dose-response curves were obtained within the range of test
concentrations, maximum E2SULT-inhibiting potencies of
only 60, 50, and 40% were found for the lower-brominated
BDE-19, BDE-47, and BDE-49, respectively (see BDE-47 in
TABLE 5
Antiandrogenic and Antiprogestagenic Potency of the 27 BFRs and Positive Controls Flutamide and RU-486 in
the AR- and PR-CALUX Assaysa
AR antagonistic PR antagonistic
Compound IC50 (lM) ± SD Flutamide EF IC50 (lM) ± SD RU-486 EF
BDE-19 0.060 ± 0.002 21.6 0.8 ± 0.4 2.6 3 104
BDE-28 3.1 ± 0.7 0.41 > 15 < 0.2 3 104
BDE-38 1.9 ± 0.6 0.69 > 15 < 0.2 3 104
BDE-39 3.5 ± 0.3 0.37 > 15 < 0.2 3 104
BDE-47 1.0 ± 0.2 1.29 > 15 < 0.2 3 104
BDE-49 0.67 ± 0.5 1.95 6.1b 0.3 3 104
BDE-79 2.0 ± 0.6 0.66 > 15 < 0.2 3 104
BDE-99 7.8 ± 3.3 0.17 > 15 < 0.2 3 104
BDE-100 0.10 ± 0.01 13.4 3.4 ± 2.4 0.6 3 104
BDE-127 5.1 ± 4.5 0.26 > 15 < 0.2 3 104
BDE-153 13.2b 0.1 5.7 ± 1.8 0.4 3 104
BDE-155 2.0b 0.64 3.8 ± 2.4 0.5 3 104
BDE-169 — —
BDE-181 3.0b 0.43 3.6 ± 1.4 0.6 3 104
BDE-183 > 15 < 0.1 2.6b 0.8 3 104
BDE-185 > 15 < 0.1 3.6 ± 0.2 0.6 3 104
BDE-190 8.8b 0.15 4.8b 0.4 3 104
BDE-206 — —
BDE-209 — —
TBBPA — —
246-TBP > 15b,c < 0.1 > 15 < 0.2 3 104
6OH-BDE-47 2.8 ± 0.4c 0.46 5.0 ± 0.9c 0.4 3 104
HBCD TM > 15 < 0.1 1.6 ± 0.0 1.3 3 104
HBCD alpha 3.4b 0.38 8.5 ± 1.5 0.2 3 104
HBCD beta 11.6 ± 3.7c > 15 < 0.2 3 104
HBCD gamma 3.7 ± 1.0 0.35 1.4 ± 0.0 1.5 3 104
TBBPA-DBPE — — —
Penta-mix 2.0b 0.65 10b 0.2 3 104
Octa-mix > 15b < 0.1 > 15b < 0.2 3 104
Flutamide 1.3 1.0 ND ND
RU-486 ND ND 0.0002 1.0
an  2; —: no response; ND: not determined.
bn ¼ 1.
cCytotoxicity was not observed, but cannot be excluded.
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Fig. 2). This probably resulted in an overestimation of their
E2SULT-inhibiting potency when BFRs were classified ac-
cording to their IC50 values (see below).
Thyroid-Related Assays
246-TBP and TBBPA were also very potent T4 competitors
in the TTR-binding assay (IC50 < 0.1lM) with a 10.2 and 1.6
times higher TTR-binding potency than the natural ligand T4
(Fig. 2; Table 7). While 6OH-BDE-47 is the third most potent
inhibitor in order and nonhydroxylated PBDEs and HBCD
have much lower T4-competing potency, a hydroxylated
aromatic group seems to be required for TTR-binding capacity.
In the absence of T3, the T-Screen–agonistic activity was
found for HBCD alpha at 1lM (up to 21% of the maximum T3-
induced proliferation; Fig. 2) and to a lesser extent for BDE-
127 and BDE-185 (Table 8). When tested in the presence of
0.25nM T3, however, 13 BFRs were able to increase the T3
response from 50 to 94% of the maximum T3-induced
response. This potentiating effect was most pronounced for
BDE-49, BDE-100, and HBCD alpha and gamma diaster-
eoisomers (Fig. 2, Table 8). In contrast, BDE-206 caused
a significant decrease in T3-induced cell proliferation at
concentrations exceeding 0.1lM (Fig. 2).
Cytotoxicity
For all BFRs, microscopic observations revealed visible
cytotoxicity in GH3 cells (T-Screen) at concentrations  1lM,
whereas no cytotoxicity was seen in any of the CALUX cells at
maximum test concentrations. Since antagonistic responses in
cell-based bioassays could be competed out in most cases by
excess of the reference agonist (100 3 EC50; data not shown),
inhibition could be attributed to true antagonism (i.e., compe-
tition for the receptor-binding sites) and not to cytotoxicity.
Antagonistic responses of 6OH-BDE-47, 246-TBP, and HBCD
TABLE 6
Estrogenic and Antiestrogenic Responses of the 27 BFRs and Positive Controls E2 and ICI 182.780 in the ER-CALUX Assaya
ER agonistic ER antagonistic
Compound EC50 (lM) ± SD E2 EF ± SD IC50 (lM) ± SD± ICI 182.780 EF ± SD
BDE-19 2.4 ± 0.1 1.3 ± 0.3 3 106 — —
BDE-28 > 15 < 0.27 3 106 — —
BDE-38 6.2 ± 1.0 0.48 ± 0.07 3 106 — —
BDE-39 — — — —
BDE-47 12 ± 4 0.35 ± 0.17 3 106 — —
BDE-49 9.2 ± 0.2 0.47 ± 0.13 3 106 — —
BDE-79 > 15 < 0.27 3 106 > 15 < 9.2 3 106
BDE-99 — — — —
BDE-100 7.0 ± 2.3 0.55 ± 0.22 3 106 — —
BDE-127 — — — —
BDE-153 — — — —
BDE-155 8.1 ± 0.9 0.52 ± 0.08 3 106 — —
BDE-169 — — — —
BDE-181 — — 4.7 ± 2.1 32 ± 14 3 106
BDE-183 — — 6.4 ± 2.9 24 ± 11 3 106
BDE-185 — — 13 ± 7 12 ± 6 3 106
BDE-190 — — 1.9 ± 1.0 83 ± 43 3 106
BDE-206 — — — —
BDE-209 — — — —
TBBPA — — — —
246-TBP — — 8.3 ± 1.2b 17 ± 2 3 106
6OH-BDE-47 — — 0.45 ± 0.03b 304 ± 22 3 106
HBCD TM — — > 15 —
HBCD alpha — — — —
HBCD beta — — 11 ± 3 13 ± 3 3 106
HBCD gamma — — 4.9 ± 0.1 29 ± 1 3 106
TBBPA-DBPE — — — —
Penta-mix — — — —
Octa-mix — — > 15 < 9.2 3 106
E2 4.0 ± 1.0 3 106 1.0 ± 0.3 ND ND
ICI 182.780 ND ND 0.14 3 103 1.0
an  2; —: no response; ND: not determined.
bCytotoxicity was not observed, but cannot be excluded.
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beta diastereoisomer in some CALUX assays could not be
competed out by excess of agonists (see footnotes in Tables 5
and 6). In these few cases, cytotoxicity may have contributed to
the antagonistic response, although microscopic cell damage
was not observed. Also, additional cell viability assays with
resazurin did not indicate cytotoxicity for these ‘‘suspected’’
BFRs in DR- and ER-CALUX cells.
Toxicity Profiling
Cytotoxicity in the T-Screen at BFR-concentrations > 1lM
hampered the calculation of full dose-response curves with
EC50 values for T3 potentiation. To enable the inclusion of T-
Screen results in a toxicity-profiling analysis together with
those from the other bioassays for which EC50 or IC50 were
available, all bioassay results were classified into dimension-
less classes according to predefined criteria (Table 3). As is the
case with EC50 or IC50 values, these classes only reflect relative
differences in ED potency of BFRs within one single bioassay,
but not among different bioassays.
After classification, compound-specific toxicity profiles
were established, which were further arranged into five
different clusters of BFRs using hierarchical cluster analysis
(Fig. 3). Cluster I consists of BFRs with moderate to very high
TTR-binding affinity and high to very high E2SULT-inhibiting
potency. This category includes the phenolic compounds 246-
TBP and TBBPA and the TBBPA derivative TBBPA-DBPE.
Cluster II consists of BDE-19, BDE-49, BDE-100, and BDE-
155 with moderate to very high antiandrogenic activity,
moderate to high antiprogestagenic and T3-potentiating activ-
ities, and moderate estrogenic activity. Cluster III consists of
HBCD (TM and the three individual diastereoisomers) and
BDE-28 with moderate to high T3-potentiating activity and
low to moderate antiandrogenic and antiprogestagenic activity
TABLE 7
T4-TTR Competing Potency and E2SULT-Inhibiting Potency of the 27 BFRs and Positive Controls T4 and PCP in
the TTR and E2SULT Assaysa
T4 replacement E2SULT inhibition
Compound IC50 (lM) T4 EF IC50 (lM) ± SD PCP EF ± SD
BDE-19 — 2.7 ± 0.0b 0.07 ± 0.03
BDE-28 — > 10 < 0.015
BDE-38 > 25 < 2.2 3 103 —
BDE-39 — —
BDE-47 > 25 < 2.2 3 103 0.8 ± 0.4b 0.23 ± 0.03
BDE-49 > 25 < 2.2 3 103 1.3b 0.18
BDE-79 — —
BDE-99 — —
BDE-100 — > 15 < 0.010
BDE-127 22 > 10 < 0.015
BDE-153 — —
BDE-155 — > 15 < 0.010
BDE-169 > 25 < 2.2 3 103 > 10 < 0.015
BDE-181 7.0 10 3 103 —
BDE-183 — > 10 < 0.015
BDE-185 7.4 —
BDE-190 9.0 8.0 3 103 3.8 ± 1.6 0.052 ± 0.049
BDE-206 — > 10
BDE-209 — > 10 < 0.015
TBBPA 0.031 1.6 0.016 ± 0.007 13 ± 12
246-TBP 0.0048 10 0.27 ± 0.23 0.82 ± 0.41
6OH-BDE-47 0.18 0.26 1.4 ± 1.5 0.18 ± 0.19
HBCD TM — —
HBCD alpha 12 2.7 3 103 —
HBCD beta 25 2.3 3 103 —
HBCD gamma — —
TBBPA-DBPE 5.2 8.6 3 103 0.27 ± 0.11 0.87 ± 0.46
Penta-mix — — > 15 < 0.010
Octa-mix — — —
T4 0.055 1.0 ND ND
PCP ND ND 0.15 ± 0.06 1.0 ± 0.4
an  2; —: no response; ND: not determined.
bE2SULT inhibitors reaching maximum inhibition levels 42–64% of the maximum PCP inhibition.
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in combination with low to moderate DR-antagonistic activity.
Cluster IV consists of tri- to hepta-brominated PBDEs and
6OH-BDE-47 with moderate to high DR-agonistic activity, in
combination with low to moderate antiandrogenic and anti-
progestagenic activities. This cluster includes a subset (IV.2) of
6OH-BDE-47, BDE-183, and BDE-190 with a very similar
profile of moderate to high ED potencies for 6 of the 12
endpoints tested (AR, PR, and ERantagonism, DR agonism,
E2SULT inhibition, and TTR-binding affinity). Cluster V
seems to consist of ‘‘rest’’ BFRs and can be divided into BFRs
without (V.1) and with (V.2) AR- and PR-antagonistic activ-
ities. BDE-47 seems to be an outlier for this cluster of BFRs, as
can be seen from its relatively long distance from the other
BFRs in cluster V.
PCA was performed on the classified toxicity profiles based
on the 10 ED endpoints for which a response was found for any
of the 27 BFRs tested (i.e., omitting the negative AR- and PR-
agonistic results found for all tested BFRs). Results from the
PCA are shown in Figure 4 as a two-dimensional score plot
with superimposed loading plot (see ‘‘Materials and Methods’’
section). To allow a direct comparison between results from
both pattern recognition methods, BFR markers in the PCA
plot have the same color as their corresponding cluster
distinguished in the hierarchical cluster analysis in Figure 3
(first column). The first PC, PC1, explained 29% of the
variation in the data set. PC1 is clearly associated with
differences in TTR-binding and E2SULT-inhibiting potencies
(cluster I) on the one hand (left side of Fig. 4) and AR- and PR-
antagonistic, ER-agonistic, and T-Screen–potentiating poten-
cies (cluster II) on the other hand (right side of Fig. 4). The
second PC, PC2, explained 21% of the variation and seems to
be associated with differences in DR-agonistic potencies
(cluster IV; top side of Fig. 4) and DR-antagonistic potencies
on the other side (clusters III and V; bottom side of Fig. 4). The
third PC, PC3, had a low significance (eigenvalue < 2) and
explained only 16% of the variation. PC3 is not shown in the
two-dimensional biplot of Figure 4, but the marker triangles for
BFRs and bioassay endpoints point in the direction by which
they were oriented in the third dimension. As can be seen from
Figure 4, PC3 roughly distinguishes between BFRs with
specific high potencies (clusters I and II) or broad potencies
(cluster IV.2) on the one hand (markers pointing up in Fig. 4)
and all remaining BFRs on the other hand (markers pointing
down). PC3 especially distinguishes among BFRs located in
the left side of Figure 4, separating potent TTR-binding and
E2SULT-inhibiting BFRs from the inactive BDE-169 and
BDE-209 and the T3-antagonistic BDE-206.
DISCUSSION
In Vitro ED Potency of BFRs
The in vitro screening demonstrated that ED mechanisms of
action that were only described for a few BFRs so far, are
shared by a wider set of BFRs than ever tested before. For
instance, AR-antagonistic potencies recently demonstrated for
penta-PBDE mixture DE-71 and BDE-100 (Sonneveld et al.,
2005; Stoker et al., 2005) were found for 18 out of the 27 BFRs
in the test set (IC50 < 15lM; Table 4). In addition, AR-
antagonistic responses were among the highest of all bioassay
responses determined in the present study, with maximum
potencies for BDE-19 and BDE-100 being higher than for
flutamide, an antiandrogenic drug used in prostate cancer
treatment. Given the presence of BDE-100 in the penta-PBDE
mixture, this relatively high AR-antagonistic potency seems to
be especially relevant. Using a QSAR model based on the AR-
CALUX results of the present study, Harju et al. (in press)
predicted AR-antagonistic activity (IC50 ¼ 0.1–3.1lM) for the
nontested penta-PBDE mixture constituents BDE-17, BDE-66,
BDE-85, and BDE-154. In general, the QSAR model predicted
high AR-antagonistic potency for low-brominated PBDEs with
ortho or ortho-para substitution. For TBBPA, the present study
TABLE 8
T3-Potentiating and T3-Antagonistic Potency of the 27 BFR
(1mM) in the T-Screena
Without T3 With EC50 T3 (0.25nM)
Compound % Effect ± SD Additional % effect ± SD
BDE-19 — 22b ± 1
BDE-28 — 33 ± 3
BDE-38 — 14c
BDE-39 — —
BDE-47 — —
BDE-49 — 44 ± 3
BDE-79 — —
BDE-99 — —
BDE-100 — 38b ± 1
BDE-127 14 ± 2 14 ± 1
BDE-153 — —
BDE-155 — 27 ± 4
BDE-169 — —
BDE-181 — —
BDE-183 — 21b ± 0
BDE-185 12 ± 2 —b
BDE-190 — —b
BDE-206 — 28b ± 2
BDE-209 — —
TBBPA — 23b,c
246-TBP — —
6OH-BDE-47 —b cytotoxic
HBCD TM — 24 ± 6
HBCD alpha 21 ± 3 38 ± 3
HBCD beta — 26c
HBCD gamma — 40c
TBBPA-DBPE — —
an  2; —: no response.
bDetermined at 0.5lM due to cytotoxicity at 1lM.
cn ¼ 1.
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confirmed a lack of AR-(ant)agonistic potency recently
reported by Kitamura et al. (2005).
In addition, PR-antagonistic potencies of BFRs have been
demonstrated for the first time. In general, PR-antagonistic
potencies were more than three orders of magnitude lower than
found for the abortifacient RU-486, of which the mechanism of
action is based on blocking PR. Especially for the lower-
brominated diphenyl ethers, a significant correlation was found
between PR-antagonistic potencies and AR-antagonistic po-
tencies (Table 5), although the first was generally lower than
the latter. The PR-antagonistic activities of HBCD and again
penta-BDE-100 seem to be especially of interest, given the
abundant presence of these BFRs in the environment. The low
PR-antagonistic activity of the penta-PBDE mixture (Table 5)
may partly be attributed to not only BDE-100 but also to BDE-
66, BDE-85, BDE-138, and BDE-154, for which Harju et al.
(in press) predicted IC50 values of 9–20lM using a QSAR
model based on the PR-CALUX results presented here. In
general, the QSAR model predicted highest PR-antagonistic
potency for PBDEs with a tri- or tetra-ortho substitution.
In contrast to the DR and ER responses, AR and PR were not
activated agonistically by any of the BFRs tested. A lack of the
AR-activating potency seems to be a general feature for
environmental AR ligands (e.g., Schreurs et al., 2005), possibly
because activation of the AR is a more complex mechanism
depending on C- and N-terminus interactions and specific
coactivators (Sonneveld et al., 2005). Similar complex activa-
tion processes may be involved in PR activation.
The T-Screen results confirmed effects of the high-production
BFRs TBBPA and HBCD on in vitro thyroid hormone–signaling
studies described before (Kitamura et al., 2002, 2005; Schriks
et al., 2006; Yamada-Okabe et al., 2005). In addition, the cur-
rent study demonstrated such potencies for another eight
PBDE congeners, of which BDE-100 and BDE-49 are the most
environmentally relevant. Interestingly, most BFRs exhibited
T-Screen activities only when tested in the presence of T3
(Table 8). For HBCD, similar results were obtained before
(Schriks et al., 2006; Yamada-Okabe et al., 2005). For TBBPA,
however, Kitamura et al. (2002, 2005) demonstrated the T3-
like activity of TBBPA in GH3 cells in both the absence and the
presence of T3. The explanation for these contradictory results
could be the use of serum-free medium in our study, excluding
the chance of any remaining T3 in the exposure mixture. The
use of serum-free medium may also (partially) explain the
FIG. 3. Hierarchical clustering analysis of the classified in vitro toxicity profiles of 27 BFRs. The relative difference in toxicity profiles between two
compounds is indicated by the horizontal distances to be bridged when moving from one compound to the other according to the branches of the dendrogram tree
shown at the right side. Numbers indicate the relative potencies for the different ED modes of action according to the criteria in Table 3. Asterisks indicate cases
with BFR dose-response curves that did not reach the maximum response of reference compounds TCDD (DR ago) or PCP (E2SULT). In these cases, EC50 and
IC50 values were calculated as the point of inflection in the compound-specific dose-response curve; ago, agonism; anta, antagonism; pot, potentiation; other
abbreviations as in Figure 2.
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differences in cytotoxicity of TBBPA, which starts at concen-
trations > 1lM in our study but did not occur until 100lM in
the study of Kitamura et al. (2005).
In a previous study on the T4-TTR–binding competition by
BFRs, Meerts et al. (2001) found no TTR binding for 17
different PBDE congeners at maximum concentrations of
0.25lM (including BDE-47, BDE-99, BDE-100, BDE-153,
and BDE-190). In the present study, TTR binding of PBDEs
was found at much higher concentrations indeed. As in the
present study, Meerts et al. (2001) also found higher TTR-
binding potencies for TBBPA and 246-TBP than for the natural
ligand T4 (Table 7). These results confirm the proposed
prerequisite for TTR-binding PCBs, i.e., hydroxylation at the
para position with one, but preferably two, adjacent halogen
substituent (Lans et al., 1993). The structure of 6OH-BDE-47
does not fully comply with this optimum prerequisite. This
may explain why the TTR-binding potency of this PBDE
metabolite is higher than for nonhydroxylated PBDEs but
lower than for TBBPA and 246-TBP.
Inhibition of E2SULT is another endocrine-related endpoint
that so far was demonstrated for a limited number of BFRs,
i.e., 246-TBP, TBBPA, and some OH-PBDE congeners
(Kester et al., 2000, 2002). As for TTR binding, Kester et al.
(2000) found highest E2SULT-inhibiting potency for coplanar
para-hydroxylated organohalogens with halogen substitution
on the phenolic ring, preferably at both places adjacent to the
hydroxy group.
Indeed, 246-TBP and TBBPA had high to very high
E2SULT-inhibiting potencies (Kester et al., 2002; Table 7),
whereas 6OH-BDE-47 (Table 7) had moderate to high inhibit-
ing potencies. Moreover, the E2SULT-inhibiting potency was
found for another four PBDEs (Table 7), although the relatively
high E2SULT-inhibiting potency of the most common conge-
ner BDE-47 (Fig. 3) is probably overestimated because it is
based on an IC50 value of 0.8lM (i.e., point of inflection in the
dose-response curve of Fig. 2). Compared to the reference
compound PCP, however, only 40% inhibition was reached at
the maximum BDE-47 concentration of 10lM (Fig. 2).
The ER-agonistic potencies found for the environmentally
relevant PBDE congeners BDE-28, BDE-47, and BDE-100
(Table 6) confirm ER-CALUX results reported by Meerts et al.
(2001). Compared to this latter study, estrogenic activity of
BDE-99 (only 2% of the maximum induction by 30pM E2) was
probably too low to be confirmed in the present study, whereas
antiestrogenic potency for BDE-153 and BDE-190 could only
be confirmed for the latter congener. The additional ER-
agonistic responses found in the present study for BDE-19,
BDE-38, BDE-49, BDE-79, and BDE-155 and ER-antagonistic
responses for hepta-brominated BDE-181, BDE-183, BDE-
185, BDE-190, and the octa-PBDE mixture (Table 6) confirm
the general observation by Meerts et al. (2001) that estrogenic
activity is associated with lower-brominated PBDEs and
antiestrogenic activity with higher-brominated PBDEs. For
estrogenic PBDEs, Meerts et al. (2001) described common
structural features as ‘‘two ortho (2,6)-bromine atoms on one
phenyl ring, at least one para-bromine (preferably on the same
phenyl ring as the ortho bromines), and nonbrominated ortho-
meta– or meta-carbons on the other phenyl ring.’’ Of the six
BDE-19
BDE-28
BDE-38
BDE-39
BDE-49
BDE-79
BDE-99 BDE-100
BDE-127
BDE-153
BDE-155
BDE-169
BDE-181
BDE-183
BDE-185
BDE-190
BDE-206
BDE-209
TBBPA
246-TBP
6OH-BDE-47
HBCD TM
HBCD alpha
HBCD beta
HBCD gamma
TBBPA-DBPE
ER ago
ER anta
TTR
DR ago
DR anta
AR anta
PR anta
E2SULT
TS pot
TS anta
Cluster I Cluster III Cluster IV.1 Cluster IV.2 Cluster V.2Cluster II Cluster V.1
PC2
PC1
BDE-47
FIG. 4. PCA ordination diagram of the 27 BFR scores (small triangles) with the superimposed loading plot showing the original 10 bioassay responses (large
triangles; AR- and PR-agonistic responses have been excluded from PCA analysis). Colors indicate the different clusters distinguished by the hierarchical
clustering in Figure 3; for each BFR and bioassay, the triangle points at the direction of ordination in the third dimension (PC3), i.e., above (D) or below (=) the
two-dimensional plane described by PC1 and PC2; ago, agonism; anta, antagonism; pot, potentiation; other abbreviations as in Figure 2.
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PBDEs with moderate ER-agonistic activity (Table 6), only
BDE-100 and BDE-155 comply with this structure-activity
relationship. The current data suggest that ER-agonistic
activity of PBDEs concurs with a [2,2#6] or a [2,2#,4] sub-
stitution and no bromine substitutions adjacent to each other.
Still, both closely related descriptions do not cover the
relatively potent 3,4,5-substituted BDE-38. With respect to
non-PBDEs, a weak agonistic (EC50 ¼ 19lM) as well as an
antagonistic (IC50  10lM) activity was found for TBBPA in
a luciferase reporter gene assay with human mammary cancer
MCF-7 cells (Kitamura et al., 2005), but not in the ER-CALUX
assay (Table 6; Meerts et al., 2001). The high antiestrogenic
activity for 6OH-BDE-47 and 246-TBP (Table 6) should be
interpreted with care. Since this ER-antagonistic activity could
not be competed out with 1000pM E2 (¼ 250 3 EC50), it is
possible that these compounds suppress the E2-induced re-
sponse by cytotoxicity, although additional cell viability assays
with resazurin did not indicate cytotoxicity for 6OH-BDE-47
or 246-TBP in ER-CALUX cells.
The present study confirms results from earlier DR-CALUX
bioassay studies, indicating that PBDEs may act as weak DR
agonists. For BDE-28, BDE-47, BDE-99, BDE-100, 246-TBP,
and HBCD (alpha, beta, and gamma diastereoisomers), the low
to absent DR-agonistic potency (Table 4) confirmed earlier
DR-CALUX results (Behnisch et al., 2003; Meerts et al., 1998;
Murk et al., 1996). Maximum DR-agonistic potencies of more
than four orders of magnitude lower than TCDD were found for
BDE-38, BDE-153, and BDE-190 (Table 4), of which the latter
two are relevant from an environmental point of view. The DR-
agonistic potency of BDE-190 was similar to that reported by
Meerts et al. (1998) but higher than found by Behnisch et al.
(2003). BDE-153 and BDE-183 showed a higher DR-agonistic
potency compared to all earlier studies (Behnisch et al., 2003;
Meerts et al., 1998; Murk et al., 1996). The relatively high DR-
agonistic potencies of [2,2#]-substituted BDE-153 and BDE-
183 are remarkable results, given the lack of DR-agonistic
potency reported for [2,2#]-substituted PCBs including PCB-
153 (Van der Plas et al., 1998). Possibly, BDE-153 fits better in
the DR-binding pocket than PCB-153 due to the presence of an
ether bridge between the two phenyl rings, which is absent in
PCB-153.
DR antagonism of BDE-28, BDE-47, BDE-99, and BDE-
100 confirmed DR-CALUX results by Meerts et al. (1998), but
potencies were higher in the present study. In both studies, the
environmentally predominant BDE-47 was the most potent
congener. In addition, DR-antagonistic responses were found
for four other PBDE congeners, the penta- and the octa-PBDE
mixtures, and HBCD (Table 4), although potencies were
moderate to low.
Except for the commercially obtained PBDEs 19, 38, 39, 79,
127, and 185, all other PBDE congeners and mixtures were
cleaned on a charcoal column before preparing stock solutions
in DMSO. Cleanup was performed to remove low levels of
DR-agonistic polybrominated dibenzofurans (PBDFs) and
dibenzo-p-dioxins (PBDDs) that may be formed during PBDE
synthesis and may act as potent DR agonists. This removal may
explain why the present study could not confirm the DR-
agonistic potency reported for noncleaned BDE-209 (Behnisch
et al., 2003). Although the contribution of PBDF and PBDD
contamination to the DR-agonistic response of BDE-38 and
BDE-79 (Table 4) is highly unlikely (Accu Standard, personal
communication), it cannot be completely excluded (A˚ke
Bergman, personal communication). Therefore, DR-agonistic
responses of these two PBDEs should be handled with care.
Non-PBDE compounds were not cleaned before preparing
stock solutions in DMSO because PBDF and PBDD formation
is not to be expected during the synthesis of these compounds.
Nevertheless, the TMs of HBCD and TBBPA-DBPE may still
be contaminated with other intermediate compounds. In
particular, a possible contamination of TBBPA-DBPE with
TBBPA could explain the (very) high potency of TBBPA-
DBPE in the TTR and E2SULT assays.
Toxicity Profiling
Hierarchical cluster analysis and PCA were used to present
the complex data set (i.e., toxic potencies of 27 BFRs towards
12 endocrine-related modes of action) in a single diagram.
Both the dendrogram in Figure 3 and the PCA plot in Figure 4
can be used to identify the most potent BFRs and their most
important modes of action. By pattern recognition, both
methods provide new information about similarity and dissim-
ilarity in toxicity profiles of the individual BFRs, which can be
indicative of structural features or other chemical character-
istics that are required for a given mode of action. In addition,
this new information can be used to design further (in vivo)
studies and to select indicator BFRs representing different
toxicity profiles that should be tested in such studies (see next
paragraph).
Cluster II (Fig. 3) for instance consists of tri- to hexa-
brominated BDE-19, BDE-49, BDE-100, and BDE-155 with
a di-ortho [2,2#] substitution and no bromine substitutions
adjacent to each other on a single aromatic ring. BDE-47 is the
only other BFR in the test set that complies with this
description. Although its toxicity profile is very similar to that
of BDE-19, BDE-49, BDE-100, and BDE-155 (four out of five
endpoints overlap), BDE-47 is not clustered accordingly in
cluster II, probably because of its lower potencies. The
similarity in profile but dissimilarity in potencies is illustrated
in the PCA plot (Fig. 4), where BDE-47 is located in between
clusters V.1 (inactive BFRs) and II, indicating that BDE-47 was
erroneously clustered with the rather inactive rest BFRs in
Figure 3.
For the HBCD TM and the three individual diaster-
eoisomers, common structural features are obvious and are
well reflected by a high correspondence in toxicity profiles
(Figs: 3 and 4). Apparently, the toxicity profile of mono-ortho–
brominated BDE-28 resembles the HBCD profile better than
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the [2,2#]-substituted PBDEs profile (cluster II), probably due
to the lower potency of BDE-28 in the various bioassays than
the PBDEs from cluster II. Cluster I contains compounds with
toxicity profiles that deviate most from all other BFRs, i.e.,
moderate to very high potency in the TTR and E2SULT assay
(Fig. 3). It contains the two hydroxylated BFRs, TBBPA and
246-TBP, as well as the TBBPA-DBPE TM, which may contain
considerable amounts of its phenolic precursor TBBPA. On the
other hand, 6OH-BDE-47 is the only hydroxylated compound
from the test set that is not clustered in cluster I, probably
because its toxic potency was not as restricted to the TTR and
E2SULT assays as it was for the BFRs from cluster I. It cannot
be excluded, however, that the moderate to high AR-, PR-, and
ER-antagonistic potencies of 6OH-BDE-47 are caused by
cytotoxicity rather than competition for receptor binding and
should therefore be classified as 1 in Figure 3. In that case, the
toxicity profile of 6OH-BDE-47 resembles that of the BFRs in
cluster I.
Resemblance in structure-activity relationships can also
explain the strong correlations between different endpoints.
For instance, the correlation between ER-agonistic, AR-
antagonistic, and PR-antagonistic potencies (Fig. 4) can be
explained by high bioassay responses of BDE-19 and BDE-
100, complying with the structural requirements for ER-
activation (i.e., low bromination with a [2,2#6] or a [2,2#,4]
substitution and no bromine substitutions adjacent to each
other), AR inactivation (low bromination with ortho or ortho-
para substitution), and PR inactivation (tri- or tetra-ortho
substitution) (this study; Harju et al., in press). As pointed out
above, the strong correlation between TTR binding and
E2SULT inhibition can be attributed to TBBPA and 246-
TBP, which comply with the similar structure-activity require-
ments for these endpoints, i.e., an OH-group with one and
preferably two adjacent bromine substituents.
Possible Implications for Human and Environmental Health
The finding that most BFRs tested in this study have
considerable antiandrogenic potency is intriguing. The anti-
androgenic potency of the environmentally relevant BDE-100
was 13 times higher than that of the well-known antiandrogenic
drug flutamide. The presence of antiandrogenic compounds,
like BFRs in the aquatic environment might present a plausible
alternative explanation for the observed alterations in fish
reproductive functions, which have so far been associated with
the presence of (xeno-)estrogens in the aquatic environment
(e.g., Sumpter, 2005). Exposure of fish to antiandrogens has
been associated with gonadal changes (induction of intersex),
reduced spermatogenesis, demasculinization, and reduced
sperm counts (Bayley et al., 2003; Kiparissis et al., 2003).
Similar changes in testicular function and sperm production
have been observed in rodents exposed to antiandrogens
(Kubota et al., 2003; Mahood et al., 2005; Uzumcu et al.,
2004) including the penta-PBDE mixture DE-71 (Stoker et al.,
2005). Further studies aim at the elucidation of the relevance of
antiandrogenicity by man-made chemicals including BFRs for
changes in reproductive functioning in fish. In the same
context, the antiprogestagenic properties of a wide set of BFRs
should be considered with concern, as Sumpter (2005) recently
stressed the extreme importance of some progesterones to fish,
in which they act as pheromones crucial for eliciting physio-
logical and behavioral responses in the other sex.
The in vitro potency of BFRs to interfere with T3-mediated
effects also deserves follow-up investigation, especially since
the T3-potentiating effect of HBCD alpha and the T3-
antagonistic effect of BDE-206 were confirmed in additional
T3-dependent in vivo assays with amphibian larvae (Schriks
et al., in press). The possibility that these compounds can affect
T3-regulated processes in animal development is especially
relevant because of their environmental relevance given the
bioaccumulating potency of HBCD alpha (Zegers et al., 2005)
and the presence of BDE-206 in sediments at relatively high
concentrations (LaGuardia et al., 2004).
For hydroxylated BFRs, the in vivo consequences of high
in vitro TTR-binding and E2SULT-inhibiting potency for pos-
sible hypothyroidal and estrogenic effects deserves further atten-
tion. This holds not only for hydroxylated parent compounds
such as TBBPA and 246-TBP but also for hydroxylated meta-
bolites of PBDEs formed by microsomal biotransformation,
which have much higher TTR-binding and E2SULT-inhibiting
potency than the parent PBDE congener (Hamers et al., in press;
Meerts et al., 2000). In addition, direct toxicity of PBDEs also
seems to be increased by hydroxylation. Additional experiments
confirm that PBDE cytotoxicity to DR- and ER-CALUX cells
increases after metabolization, especially for lower-brominated
BFRs (Hamers et al., in press).
Based on these new insights, implications for human and
environmental health are expected for BFRs grouped in
clusters I (TTR-binding and E2SULT inhibition), II (antian-
drogenicity and antiprogestagenicity), and III (as II with T3
potentiation). For a more elaborate hazard assessment, we
therefore suggest to test the in vivo ED potency of TBBPA,
BDE-100, and HBCD, which are representative BFRs for
clusters I, II, and III, respectively, with high environmental
relevance. Special attention should be given to hypothyroidal
and estrogenic effects of TBBPA, to estrogenic, antiandroge-
nic, antiprogestagenic, and hyperthyroidal effects of BDE-100,
and to antiandrogenic, antiprogestagenic, and hyperthyroidal
effects of HBCD.
CONCLUDING REMARKS
The systematic screening demonstrated in vitro ED poten-
cies for a wider set of BFRs and for more modes of action than
was ever tested before. Antiandrogenic, antiprogestagenic,
(anti-)estrogenic, (anti–)dioxin-like, and T3-antagonistic po-
tencies of BFRs were demonstrated at the receptor level. In
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addition, ED potencies of BFRs were revealed that are not
directly linked to receptor (in-)activation, namely protein-
binding (TTR), enzyme inhibition (E2SULT), and potentiation
of T3-mediated effects. For some BFRs, the ED potency was
higher than for natural ligands or clinical drugs used as positive
controls, viz, AR antagonism by di-ortho-[2,2#]-substituted
PBDEs with no bromine substitutions adjacent to each other,
and T4-TTR competition and E2SULT inhibition by hydrox-
ylated BFRs. Based on similarity in ED profiles, BFRs could be
classified into five different clusters. TBBPA, BDE-100, and
HBCD were identified as the most environmentally relevant
BFRs representing different toxicity profiles. These findings
support further investigation of the potential ED effects of these
BFRs in man and wildlife.
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